COSTANTINO, Luca
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 20.725
EU - Europa 8.308
AS - Asia 6.853
SA - Sud America 954
AF - Africa 127
OC - Oceania 28
Continente sconosciuto - Info sul continente non disponibili 12
Totale 37.007
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 20.575
GB - Regno Unito 3.061
CN - Cina 2.355
SG - Singapore 2.116
IT - Italia 1.369
SE - Svezia 1.041
HK - Hong Kong 903
BR - Brasile 786
DE - Germania 781
UA - Ucraina 474
RU - Federazione Russa 440
TR - Turchia 374
VN - Vietnam 343
FI - Finlandia 254
KR - Corea 232
FR - Francia 227
BG - Bulgaria 176
IN - India 149
NL - Olanda 94
CA - Canada 83
JP - Giappone 66
AR - Argentina 64
ID - Indonesia 63
PL - Polonia 55
ZA - Sudafrica 51
BD - Bangladesh 50
IE - Irlanda 50
BE - Belgio 46
MX - Messico 40
ES - Italia 39
IQ - Iraq 37
CH - Svizzera 35
LT - Lituania 27
EC - Ecuador 26
RO - Romania 25
AU - Australia 24
IR - Iran 20
AE - Emirati Arabi Uniti 18
AT - Austria 17
PY - Paraguay 17
CL - Cile 16
PT - Portogallo 16
EG - Egitto 15
CO - Colombia 14
MA - Marocco 14
MD - Moldavia 14
PK - Pakistan 14
TW - Taiwan 14
CZ - Repubblica Ceca 13
VE - Venezuela 12
EU - Europa 11
UZ - Uzbekistan 11
UY - Uruguay 10
AZ - Azerbaigian 8
GR - Grecia 8
JO - Giordania 8
KE - Kenya 8
NO - Norvegia 8
IL - Israele 7
PE - Perù 7
SA - Arabia Saudita 7
TN - Tunisia 7
BY - Bielorussia 6
DK - Danimarca 6
DZ - Algeria 6
RS - Serbia 6
SN - Senegal 6
EE - Estonia 5
KZ - Kazakistan 5
MY - Malesia 5
NP - Nepal 5
PH - Filippine 5
AL - Albania 4
BZ - Belize 4
GE - Georgia 4
KG - Kirghizistan 4
LB - Libano 4
LK - Sri Lanka 4
NG - Nigeria 4
NZ - Nuova Zelanda 4
TH - Thailandia 4
AO - Angola 3
DO - Repubblica Dominicana 3
GT - Guatemala 3
HU - Ungheria 3
JM - Giamaica 3
NI - Nicaragua 3
TZ - Tanzania 3
BH - Bahrain 2
CI - Costa d'Avorio 2
CR - Costa Rica 2
ET - Etiopia 2
HN - Honduras 2
HR - Croazia 2
KH - Cambogia 2
KW - Kuwait 2
LA - Repubblica Popolare Democratica del Laos 2
LV - Lettonia 2
PA - Panama 2
PS - Palestinian Territory 2
Totale 36.981
Salva come PNG Salva come JPEG
Città #
Southend 2.220
Fairfield 2.116
Santa Clara 1.810
Ashburn 1.550
Woodbridge 1.451
Singapore 1.263
Chandler 1.119
Houston 1.025
Seattle 941
Jacksonville 939
Hong Kong 897
Hefei 857
Wilmington 819
Ann Arbor 788
Dearborn 751
Cambridge 741
Chicago 579
Nyköping 559
Los Angeles 416
London 404
Beijing 377
Salt Lake City 259
Modena 225
Izmir 204
San Diego 202
Princeton 198
Seoul 187
Council Bluffs 172
Sofia 170
Eugene 166
The Dalles 137
New York 130
Frankfurt am Main 129
Bremen 125
Dallas 123
Moscow 123
Buffalo 122
Ho Chi Minh City 119
Shanghai 103
Elk Grove Village 101
Redwood City 98
Helsinki 95
Tampa 90
Milan 87
Hanoi 77
Des Moines 69
São Paulo 57
Lancaster 55
Munich 55
Rome 53
Tokyo 53
Sterling 52
Bologna 48
Dublin 48
Fremont 48
Columbus 47
Guangzhou 45
Phoenix 38
Verona 37
Miami 36
Boardman 35
Nanjing 35
Atlanta 33
Parma 31
Denver 30
Jakarta 30
Norwalk 30
Brussels 29
San Jose 29
Jinan 27
Kunming 27
Napoli 26
Philadelphia 26
Detroit 25
Montreal 25
Rio de Janeiro 25
Dulles 24
Orem 24
San Francisco 24
Brooklyn 23
Belo Horizonte 22
Stockholm 22
Chennai 21
Toronto 20
Groningen 19
Kraków 19
Naples 19
Warsaw 19
Kent 18
Mexico City 18
Amsterdam 17
Falls Church 17
Haiphong 17
Pittsburgh 17
Saint Petersburg 17
San Mateo 17
Zhengzhou 17
Cape Town 16
Marseille 16
Sassuolo 16
Totale 26.727
Salva come PNG Salva come JPEG
Nome #
Targeting the Central Nervous System: in vivo experiments with peptide-derivatized nanoparticles loaded with Loperamide and Rhodamine-123 429
1-Benzopyran-4-one antioxidants as aldose reductase inhibitors 417
Discovery of a benzothiophene-flavonol halting miltefosine and antimonial drug resistance in Leishmania parasites through the application of medicinal chemistry, screening and genomics 402
PLGA nanoparticles surface decorated with the sialic acid, N-acetylneuraminic acid 394
Nanoparticulate drug carriers based on hybrid poly(D,L-lactide-co-glycolide)-dendron structures 388
7-Hydroxy-2-substituted-4-H-1-benzopyran-4-one derivatives as aldose reductase inhibitors: a SAR study 379
The Impact of Lipid Corona on Rifampicin Intramacrophagic Transport Using Inhaled Solid Lipid Nanoparticles Surface-Decorated with a Mannosylated Surfactant 373
Nanoparticles as drug delivery agents specific for CNS: in vivo biodistribution 369
Aryl thiosemicarbazones for the treatment of trypanosomatidic infections 362
Synthesis, activity and molecular modeling of a new series of chromones as low molecular weight protein tyrosine phosphatase inhibitors 360
Sialic acid and glycopeptides conjugated PLGA nanoparticles for central nervous system targeting: In vivo pharmacological evidence and biodistribution 354
Enhancement of Benzothiazoles as Pteridine Reductase-1 Inhibitors for the Treatment of Trypanosomatidic Infections 353
Peptide-derivatized biodegradable nanoparticles able to cross the blood-brain barrier 343
Laboratorio di Preparazione Estrattiva e Sintetica dei Farmaci 341
Synthesis and biological evaluation of new imidazole, pyrimidine, and purine derivatives and analogs as inhibitors of xanthine oxidase 339
Privileged structures as leads in medicinal chemistry 335
Polymeric nanoparticles for the drug delivery to the central nervous system 326
A rational approach to the design of flavones as xanthine oxidase inhibitors 320
Profiling of Flavonol Derivatives for the Development of Antitrypanosomatidic Drugs 315
2′-Deoxyuridine 5′-Monophosphate Substrate Displacement in Thymidylate Synthase through 6-Hydroxy-2H-naphtho[1,8-bc]furan-2-one Derivatives 314
STAT3 as Target for cancer drug discovery 313
Is there a clinical future for polymeric nanoparticles as brain targeting drug delivery agents? 308
NUOVE MOLECOLE, PER USO COME AGENTI ANTITUMORALI 304
Synthesis and structure-activity relationships of 1-aralkyl-4- benzylpiperidine and 1-aralkyl-4-benzylpiperazine derivatives as potent σ ligands 297
Challenges in the design of clinically useful brain-targeted drug nanocarriers 296
Current and Future Chemotherapy for Chagas Disease 296
Aldose reductase does catalyse the reduction of glyceraldehyde through a stoichiometric oxidation of NADPH. 295
Conjugated poly(D,L-lactide-co-glycolide) for the preparation of in vivo detectable nanoparticles 294
ANTIINFLAMMATORY ACTIVITY OF NEWLY SYNTHESIZED 2,6-BIS-(1,1-DIMETHYLETHYL)PHENOL DERIVATIVES 290
ANTICANCER DRUGS 283
Synthesis, activity, and molecular modeling of a new series of tricyclic pyridazinones as selective aldose reductase inhibitors 282
Designed multiple ligands: basic research vs clinical outcomes 281
Exploiting the 2-Amino-1,3,4-thiadiazole Scaffold To InhibitTrypanosoma bruceiPteridine Reductase in Support of Early-Stage Drug Discovery 281
Synthesis and description of chalcone-like compounds, inhibitors of aldose reductase 281
Methoxylated 2'-hydroxychalcones as antiparasitic hit compounds 279
Surface engineering of Solid Lipid Nanoparticle assemblies by methyl α-d-mannopyranoside for the active targeting to macrophages in anti-tuberculosis inhalation therapy 277
A model of the interaction of substrates and inhibitors with xanthine oxidase 274
Colloidal systems for CNS drug delivery 270
Anti-TB inhalation therapy: Design of mannose-based functionalised Solid Lipid Microparticles for an active targeting to alveolar macrophages 269
New aldose reductase inhibitors as potential agents for the prevention of long-term diabetic complications 267
Activity of polyphenolic crude extracts as scavengers of superoxide radicals and inhibitors of xanthine oxidase 266
Development of flavonoids derivatives as leads against Leishmaniasis and Trypanosomiasis-invited lecture 265
Structure-based design of an inhibitor modeled at the substrate active site of aldose reductase 264
Synthesis and aldose reductase inhibitory activity of benzoyl-amino acid derivatives 261
Synthesis and activity of a new series of chalcones as aldose reductase inhibitors 260
SAR Studies and Biological Characterization of a Chromen-4-one Derivative as an Anti-Trypanosoma brucei Agent 258
Applicazione delle tecniche microscopiche, spettroscopiche e calorimetriche nella caratterizzazione di nanoparticelle funzionalizzate 257
Binding of 1-benzopyran-4-one derivatives to aldose reductase: A free energy perturbation study 257
Ghrelin receptor modulators and their therapeutic potential 256
Glycopeptide-decorated nanoparticles as drug carriers for CNS: effects of surface coverage and carbohydrate type 253
A series of diarylsubstituted oximes as potential substrates for new aldose reductase inhibitors 250
Diabetes complications and their potential prevention: Aldose reductase inhibition and other approaches 250
Structural bases for the inhibition of aldose reductase by phenolic compounds 246
Design, synthesis and biological evaluation of non-covalent AmpC Beta-Lactamases inhibitors 246
Ghrelin receptor modulators: a patent review (2011-2014) 246
Isolation and Pharmacological Activities of the Tecoma stans Alkaloids 242
Iron acquisition pathways as targets for antitubercular drugs 242
Folate: Relevance of Chemical and Microbial Production 239
Peptide-derivatized biodegradable nanoparticles able to cross the blood brain barrier 238
Soft docking and multiple receptor conformations in virtual screening. 237
Magnetic and Optical Bistability in Tetrairon(III) Single Molecule Magnets Functionalized with Azobenzene Groups 236
Novel engineered lipid-based nanoparticles for pulmonary tuberculosis inhalation therapy 232
Solvent effects on the tautomerism of apigeninidin 230
Small-angle neutron scattering characterization of liposomes for anti-tuberculosis inhaled therapy. 228
ANTHOCYANIDINES AS INHIBITORS OF XANTHINE-OXIDASE 227
Physico-chemical properties of anthocyanidins. Part 1. Theoretical evaluation of the stability of the neutral and anionic tautomeric forms 226
Identificazione, caratterizzazione e proprietà biologiche di derivati calconici da GLYCYRRHIZA GLABRA L. 224
Cell internalization study of hybrid chitosan-heparin-PLGA nanocarriers on Caco-2 cells 223
Synthesis and Aldose reductase inhibitory activity of 5-arylidene-2,4-thiazolidinediones. 221
Binding of beta-carbolines and related agents at serotonin (5-HT-2 and 5-HT-1A), dopamine (D-2) and benzodiazepine receptors 220
Activité Antilipoperoxydante d'Extraits Polyphenoliques de Ribes Nigrum L. 220
Fragment Based Discovery of Thymidylate Synthase Dimeric Interface Inhibitors Through Mass Spectrometry. Invited lecture to the Fragment Based Lead Discovery track. 220
In Vivo Biodistribution of Respirable Solid Lipid Nanoparticles Surface-Decorated with a Mannose-Based Surfactant: A Promising Tool for Pulmonary Tuberculosis Treatment? 219
Pharmacological approaches to the treatment of diabetic complications 218
COMPOSTI AD ATTIVITÀ ANTIPARASSITARIA 218
Engineered polylactide-co-glycolide(PLGA) Np as drug delivery systems for the Central Nervous System 217
Quantitative measurement of proton dissociation and tautomeric constants of apigeninidin 217
Destabilizers of the thymidylate synthase homodimer accelerate its proteasomal degradation and inhibit cancer growth 214
Drugs/lamellae interface influences the inner structure of double-loaded liposomes for inhaled anti-TB therapy: An in-depth small-angle neutron scattering investigation 213
Nitrophenyl derivatives as Aldose Reductase inhibitors 212
Composition, Superoxide Radicals Scavenging and Antilipoperoxidant Activity of some Edible Fruits 211
Pathophysiogenesis of Mesial Temporal Lobe Epilepsy: Is Prevention of Damage Antiepileptogenic? 211
Unusual Targeting of the human Thymidylate synthase interface: a tethering approach with mass-spectrometric detection. 207
Synthesis of novel benzoic acid derivatives with benzothiazolyl subunit and evaluation as aldose reductase inhibitors 207
Discovery of new inhibitors of aldose reductase from molecular docking and database screening 206
On the prodrug-potential of novel Aldose reductase inhibitors with diphenylmethyleneaminooxycarboxylic acid structure 205
Aerodynamic performance of lipid-based nanocarrier functionalized by novel mannose derivatives for Rifampicin intramacrophagic delivery 205
Isoxazolo-[3,4-d]-pyridazin-7-(6H)-one as a potential substrate for new aldose reductase inhibitors 204
Interaction of nanoparticles with immunocompetent cells: nanosafety considerations. 204
Nanoparticelle per il direzionamento cerebrale di farmaci 203
Modified PLGA Nanoparticles as drug carriers for CNS delivery 203
Synthesis and aldose reductase inhibitory activity of a new series of benzo[h]cinnolinone derivatives 203
Surface decorated nanoparticles as drug delivery agents to the brain 202
Synthesis and aldose reductase inhibitory activities of novel thienocinnolinone derivatives 199
Theoretical and experimental study of flavones as inhibitors of xanthine oxidase 199
Nose-to-brain drug delivery by nanoparticles in the treatment of neurological disorders 198
Nanoparticles for drug delivery to the CNS 197
Molecular dynamics simulations of the structure of aldose reductase complexed with the inhibitor Tolrestat 197
Heteroarylalkanoic acids with possible antiinflammatory activities, III 196
Oxidative modification of aldose reductase induced by copper ion. Factors and conditions affecting the process 196
Totale 26.471
Salva come PNG Salva come JPEG
Categoria #
all - tutte 143.539
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 143.539
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/20212.527 0 0 0 0 0 317 323 491 214 708 298 176
2021/20223.031 93 396 425 199 79 155 167 206 290 200 487 334
2022/20233.139 417 341 225 281 420 479 73 246 410 54 114 79
2023/20241.868 69 119 105 191 431 178 177 246 57 51 79 165
2024/20256.613 287 86 133 447 1.315 925 450 424 663 416 696 771
2025/20267.400 696 503 1.195 1.752 2.514 740 0 0 0 0 0 0
Totale 37.226